Amgen and Allergan, which started their collaboration back in 2011 when Allergan was a generic drug maker called Watson Pharmaceuticals, released few details but said the drug ABP 215 had shown clinical equivalence to Avastin as measured by tumor shrinkage, duration of response and progression-free survival. Launched in 2004, Avastin is drawing $7 billion for Roche as a treatment for a variety of different cancers, about 20% to 25% of it from lung cancer.